Evidence map›Paper›PMID 34241729›Full record

ArticleNeurosurgical review2022

Do elderly patients (≥ 75 years old) with glioblastoma benefit from more radical surgeries in the era of temozolomide?

Tengfei Li, Yanhui Liu, Junhong Li, Mingrong Zuo, Yongzhong Cheng

Abstract read
PubMed Publisher
In one paragraph

Article in Neurosurgical review, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Optimal managements of elderly patients with glioblastoma.Japanese journal of clinical oncology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Tengfei LiDepartment of Neurosurgery, West China Hospital, Sichuan Province, Chengdu, People's Republic of China.
Yanhui LiuDepartment of Neurosurgery, West China Hospital, Sichuan Province, Chengdu, People's Republic of China.
Junhong LiDepartment of Neurosurgery, West China Hospital, Sichuan Province, Chengdu, People's Republic of China.
Mingrong ZuoDepartment of Neurosurgery, West China Hospital, Sichuan Province, Chengdu, People's Republic of China.
Yongzhong ChengDepartment of Neurosurgery, West China Hospital, Sichuan Province, Chengdu, People's Republic of China. cyz2018259@163.com.ORCID http://orcid.org/0000-0003-4779-5077
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study assesses the effect of extent of resection (EOR) on the longer-term survival and early mortality of elderly patients (≥ 75 years old) with glioblastoma. We used the Surveillance, Epidemiology, and End Results (SEER) database and data from our center to evaluate the effect of EOR on the long-term survival and early mortality of patients with glioblastoma. We included 50 elderly patients (≥ 75 years old) with glioblastoma visiting our hospital. The median overall survival of the patients who underwent a gross total resection, a subtotal resection, and a partial resection were 278, 200, and 83 days, respectively. The multivariate analysis showed that gross total resection (HR: 0.100; 95% CI: 0.015-0.671, p < 0.001) and subtotal reresection (HR: 0.134, 95% CI: 0.022-0.831, p < 0.001) were independent predictors of favorable prognosis when compared with partial resection. The data extracted from the SEER database also indicated that EOR was an independent predictor of OS, CCS, and early mortality. The stratification analysis revealed that gross total resection was the best protective factor of OS, early mortality, and CCS. Radical resection may improve the OS and CCS of glioblastoma patients aged ≥ 75 years and decrease early mortality.

Indexed as

Brain NeoplasmsGlioblastomaAgedHumansNeurosurgical ProceduresPrognosisRetrospective StudiesTemozolomideTreatment OutcomeTemozolomideEarly mortalityExtent of resectionGlioblastomaOverall survival

Identifiers

PMID34241729
OpenAlexW3179556936

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.